


Figure S9



Supplementary information, Fig S9. Therapeutic resistance to anti-PD-1 mAb is Arginase 1 independent.

(a-b) *In vitro* assays. Relative expression of *Arg1* quantified by qRT-PCR following stimulations of various tumor cell lines or BMDCs and BMMCs with either IFN α , IFN γ or LPS. Each dot represents one stimulated sample and graphs represent 1 experiment or are the pool of 2 independent experiments including biological replicates for each experiment. Statistical analyses were performed using unpaired t-tests to compare two groups or ANOVA statistical tests and pairwise comparisons with Bonferroni adjustment for more than two groups. (c) *In vivo* experiments. Cell sorting by flow cytometry of CD45⁺ (left panel) and CD45⁻ (right panel) fractions from the TME of MCA205WT 48 hrs after 1, 2, 3 or 4 i.p. administrations of anti-PD-1 (or isotype control) mAbs followed by qRT-PCR quantifying the *Arg1* relative expression. Each dot represents 1 tumor. Graphs represent the pool of 2 experiments with 4-5 mice per group, per time point and per experiment. (d) Tumor growth kinetics and Kaplan Meier survival curves of *Arg1^{fl/fl}* and *Arg1^{fl/fl}Tie2^{Cre/+}* mice inoculated with the MCA205WT tumor model and treated with anti-PD-1 or its isotype control mAbs. Statistical analyses were performed using the specific software detailed in the Materials and Methods. Data are representative of 1 experiment with 5 mice per group. * $p < 0.05$, ** $p < 0.01$, n.s.: not significant.